In this market? It means little - but we'll give it the college try... starting a 1.5% stake in the $153 area. Again, let me say almost every stock is a hostage to the indexes - so at this time it is sort of immaterial what individual stocks you own - if the charts on the indexes improve I expect a lot of money to come in to take almost everything up. And the opposite if we break back down. If Mastercard falls back below $148 on a closing basis we'll retrench and cut back on the position. If the stock gets north of $170 it has a lot of headroom to run but we take it hour by hour around here lately... can't look past out your nose.Mastercard is one of my favorite companies in terms of business fundamentals so if I'm going to add some long exposure, this is a name to try it with. But everything lies in the market with "student body left" type of trading we've been stuck with for the better part of 9 months.... the indexes rule the individual stocks.
Long Mastercard in fund; no personal position
4 comments:
Any thoughts on CVTX being bought for $20/share but trading in the $20.60s? Absent a bidding war, I don't see a higher price for it, and management is supporting the deal and recommending share holders take it. Do you know of any precedent for this, or is it a free short you think?
I don't follow it Robert but one of my readers owns a batch, I will send him an email to come comment
Oh, looks like the market is looking for a counter bid from Astellas, which earlier offered $16.
Yes, the market is looking for a counter bid from, at the least, Astellas. There is much more in the CV portfolio than Ranexa. Lexiscan is picking up and CV does have stent coating underway. There are a few other companies that CV would fit well with.
Bidding war would obviously be the only reason for a higher price. Its all a toss up.
-H
Post a Comment